X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11160) 11160
Newspaper Article (434) 434
Newsletter (72) 72
Book Chapter (33) 33
Magazine Article (16) 16
Conference Proceeding (6) 6
Trade Publication Article (5) 5
Publication (3) 3
Reference (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (8862) 8862
humans (8088) 8088
life sciences & biomedicine (7580) 7580
female (4865) 4865
male (4643) 4643
middle aged (3552) 3552
adult (3186) 3186
polyethylene glycol (3055) 3055
polyethylene glycols - adverse effects (2842) 2842
polyethylene glycols - therapeutic use (2725) 2725
animals (2468) 2468
polyethylene glycols - administration & dosage (2244) 2244
treatment outcome (2238) 2238
aged (2199) 2199
interferon-alpha - therapeutic use (1899) 1899
hepatitis c, chronic - drug therapy (1854) 1854
antiviral agents - therapeutic use (1779) 1779
recombinant proteins (1724) 1724
drug therapy, combination (1692) 1692
gastroenterology & hepatology (1647) 1647
polyethylene glycols - chemistry (1632) 1632
pharmacology & pharmacy (1553) 1553
ribavirin - therapeutic use (1505) 1505
interferon-alpha - adverse effects (1460) 1460
antiviral agents - adverse effects (1419) 1419
polyethylene glycols (1383) 1383
hepatitis c (1142) 1142
oncology (1112) 1112
technology (1089) 1089
recombinant proteins - therapeutic use (1037) 1037
analysis (1024) 1024
care and treatment (990) 990
interferon-alpha - administration & dosage (981) 981
materials science (978) 978
ribavirin - adverse effects (958) 958
mice (943) 943
interferon (896) 896
drug delivery systems (872) 872
ribavirin (872) 872
science & technology - other topics (869) 869
health aspects (863) 863
antiviral agents - administration & dosage (853) 853
hepacivirus - genetics (850) 850
nanoparticles (848) 848
cancer (845) 845
physical sciences (823) 823
research (808) 808
genotype (789) 789
ribavirin - administration & dosage (788) 788
time factors (768) 768
engineering (740) 740
prospective studies (732) 732
materials science, biomaterials (705) 705
adolescent (704) 704
chemistry (699) 699
young adult (692) 692
abridged index medicus (681) 681
drug therapy (670) 670
hepatitis c virus (670) 670
surgery (664) 664
recombinant proteins - adverse effects (659) 659
rats (655) 655
engineering, biomedical (648) 648
polyethylene glycols - pharmacology (647) 647
medicine (632) 632
polyethylene (631) 631
retrospective studies (617) 617
chemotherapy (614) 614
hepatitis c - drug therapy (602) 602
drugs (597) 597
recombinant proteins - administration & dosage (579) 579
dose-response relationship, drug (578) 578
aged, 80 and over (553) 553
risk factors (549) 549
clinical trials (542) 542
medicine & public health (540) 540
drug administration schedule (539) 539
hepatitis c, chronic - virology (537) 537
biological response modifiers (524) 524
nanoscience & nanotechnology (523) 523
doxorubicin - administration & dosage (499) 499
proteins (496) 496
doxorubicin - analogs & derivatives (478) 478
viral load (477) 477
cell line, tumor (475) 475
hepacivirus - drug effects (473) 473
polyols (468) 468
research article (468) 468
hepatitis (458) 458
polymers (452) 452
patients (451) 451
studies (437) 437
follow-up studies (435) 435
tumors (426) 426
colonoscopy (423) 423
dentistry (419) 419
infectious diseases (415) 415
chemistry, multidisciplinary (414) 414
biocompatibility (413) 413
particle size (411) 411
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11347) 11347
Spanish (104) 104
German (103) 103
Japanese (83) 83
French (81) 81
Chinese (55) 55
Portuguese (33) 33
Russian (28) 28
Polish (19) 19
Korean (18) 18
Hungarian (12) 12
Italian (10) 10
Dutch (9) 9
Persian (6) 6
Serbian (6) 6
Czech (5) 5
Danish (5) 5
Norwegian (4) 4
Swedish (4) 4
Croatian (3) 3
Romanian (3) 3
Turkish (2) 2
Ukrainian (2) 2
Hebrew (1) 1
Icelandic (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 05/2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Clinical cancer research, ISSN 1557-3265, 09/2010, Volume 16, Issue 24, pp. 6139 - 6149
Journal Article
Journal of controlled release, ISSN 0168-3659, 08/2017, Volume 260, pp. 46 - 60
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 06/2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 07/2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection | Index Medicus
Journal Article